{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:55:59Z","timestamp":1783698959168,"version":"3.55.0"},"reference-count":29,"publisher":"Japan Endocrine Society","issue":"10","funder":[{"name":"National Center for Global Health and Medicine, Japan","award":["27-1402"],"award-info":[{"award-number":["27-1402"]}]},{"name":"National Center for Global Health and Medicine, Japan","award":["30-1008"],"award-info":[{"award-number":["30-1008"]}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare of Japan","doi-asserted-by":"crossref","award":["Nanbyo-Ippan-23FC0201"],"award-info":[{"award-number":["Nanbyo-Ippan-23FC0201"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1507\/endocrj.ej24-0696","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T18:07:26Z","timestamp":1750270046000},"page":"1079-1088","source":"Crossref","is-referenced-by-count":3,"title":["Safety management in Cushing syndrome during osilodrostat treatment based on morning blood cortisol level"],"prefix":"10.1507","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0396-8645","authenticated-orcid":false,"given":"Takuyuki","family":"Katabami","sequence":"first","affiliation":[{"name":"Department of Metabolism and Endocrinology, St. Marianna University Yokohama Seibu Hospital, Yokohama 241-0811, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5041-6344","authenticated-orcid":false,"given":"Ren","family":"Matsuba","sequence":"additional","affiliation":[{"name":"Department of Metabolism and Endocrinology, St. Marianna University Yokohama Seibu Hospital, Yokohama 241-0811, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0647-4593","authenticated-orcid":false,"given":"Tomoyuki","family":"Nagasaka","sequence":"additional","affiliation":[{"name":"Department of Metabolism and Endocrinology, St. Marianna University Yokohama Seibu Hospital, Yokohama 241-0811, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5728-5955","authenticated-orcid":false,"given":"Yutaro","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Metabolism and Endocrinology, St. Marianna University Yokohama Seibu Hospital, Yokohama 241-0811, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3452-116X","authenticated-orcid":false,"given":"Kensuke","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Metabolism and Endocrinology, St. Marianna University Yokohama Seibu Hospital, Yokohama 241-0811, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0757-7529","authenticated-orcid":false,"given":"Masakatsu","family":"Sone","sequence":"additional","affiliation":[{"name":"Department of Metabolism and Endocrinology, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Webb SM, Valassi E (2022) Quality of life impairment after a diagnosis of Cushing\u2019s syndrome. Pituitary 25: 768\u2013771.","DOI":"10.1007\/s11102-022-01245-9"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, et al. (2021) Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol 9: 847\u2013875.","DOI":"10.1016\/S2213-8587(21)00235-7"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Mondin A, Ceccato F, Voltan G, Mazzeo P, Manara R, et al. (2023) Complications and mortality of Cushing\u2019s disease: report on data collected over a 20-year period at a referral centre. Pituitary 26: 551\u2013560.","DOI":"10.1007\/s11102-023-01343-2"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Araujo-Castro M, Pascual-Corrales E, Lamas C (2023) Possible, probable, and certain hypercortisolism: a continuum in the risk of comorbidity. Ann Endocrinol (Paris) 84: 272\u2013284.","DOI":"10.1016\/j.ando.2023.01.005"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BM, et al. (2016) Complications of Cushing\u2019s syndrome: state of the art. Lancet Diabetes Endocrinol 4: 611\u2013629.","DOI":"10.1016\/S2213-8587(16)00086-3"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Sim\u00f5es Corr\u00eaa Galendi J, Correa Neto ANS, Demetres M, Boguszewski CL, Nogueira V (2021) Effectiveness of medical treatment of Cushing\u2019s disease: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 12: 732240.","DOI":"10.3389\/fendo.2021.732240"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Daniel E, Aylwin S, Mustafa O, Ball S, Munir A, et al. (2015) Effectiveness of metyrapone in treating Cushing\u2019s syndrome: a retrospective multicenter study in 195 patients. J Clin Endocrinol Metab 100: 4146\u20134154.","DOI":"10.1210\/jc.2015-2616"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Duggan S (2020) Osilodrostat: first approval. Drugs 80: 495\u2013500.","DOI":"10.1007\/s40265-020-01277-0"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, et al. (2020) Efficacy and safety of osilodrostat in patients with Cushing\u2019s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol 8: 748\u2013761.","DOI":"10.1016\/S2213-8587(20)30240-0"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Bertagna X, Pivonello R, Fleseriu M, Zhang Y, Robinson P, et al. (2014) LCI699, a potent 11\u03b2-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing\u2019s disease: results from a multicenter, proof-of-concept study. J Clin Endocrinol Metab 99: 1375\u20131383.","DOI":"10.1210\/jc.2013-2117"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Fleseriu M, Biller BMK, Bertherat J, Young J, Hatipoglu B, et al. (2022) Long-term efficacy and safety of osilodrostat in Cushing\u2019s disease: final results from a Phase II study with an optional extension phase (LINC 2). Pituitary 25: 959\u2013970.","DOI":"10.1007\/s11102-022-01280-6"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Gadelha M, Bex M, Feelders RA, Heaney AP, Auchus RJ, et al. (2022) Randomized trial of osilodrostat for the treatment of Cushing disease. J Clin Endocrinol Metab 107: e2882\u2013e2895.","DOI":"10.1210\/clinem\/dgac178"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Ceccato F, Boscaro M (2016) Cushing\u2019s syndrome: screening and diagnosis. High Blood Press Cardiovasc Prev 23: 209\u2013215.","DOI":"10.1007\/s40292-016-0153-4"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 de Miguel Novoa P, Vela ET, Garc\u00eda NP, Rodr\u00edguez MM, Guerras IS, et al. (2014) Guidelines for the diagnosis and treatment of adrenal insufficiency in the adult. Endocrinol Nutr 61 Suppl 1: 1\u201335.","DOI":"10.1016\/S2173-5093(14)70069-8"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, et al. (2008) The diagnosis of Cushing\u2019s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93: 1526\u20131540.","DOI":"10.1210\/jc.2008-0125"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Petersenn S (2022) Overnight 1 mg dexamethasone suppression test and 24 h urine free cortisol-accuracy and pitfalls when screening for Cushing\u2019s syndrome. Pituitary 25: 693\u2013697.","DOI":"10.1007\/s11102-022-01249-5"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, et al. (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982\u2013992.","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, et al. (2016) Diagnosis and treatment of primary adrenal insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 101: 364\u2013389.","DOI":"10.1210\/jc.2015-1710"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Yanase T, Tajima T, Katabami T, Iwasaki Y, Tanahashi Y, et al. (2016) Diagnosis and treatment of adrenal insufficiency including adrenal crisis: a Japan Endocrine Society clinical practice guideline [Opinion]. Endocr J 63: 765\u2013784.","DOI":"10.1507\/endocrj.EJ16-0242"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Stuijver DJ, van Zaane B, Feelders RA, Debeij J, Cannegieter SC, et al. (2011) Incidence of venous thromboembolism in patients with Cushing\u2019s syndrome: a multicenter cohort study. J Clin Endocrinol Metab 96: 3525\u20133532.","DOI":"10.1210\/jc.2011-1661"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Pivonello R, De Leo M, Cozzolino A, Colao A (2015) The treatment of Cushing\u2019s disease. Endocr Rev 36: 385\u2013486.","DOI":"10.1210\/er.2013-1048"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Dormoy A, Haissaguerre M, Vitellius G, Do Cao C, Geslot A, et al. (2023) Efficacy and safety of osilodrostat in paraneoplastic Cushing syndrome: a real-world multicenter study in France. J Clin Endocrinol Metab 108: 1475\u20131487.","DOI":"10.1210\/clinem\/dgac691"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Lee DY, Kim E, Choi MH (2015) Technical and clinical aspects of cortisol as a biochemical marker of chronic stress. BMB Rep 48: 209\u2013216.","DOI":"10.5483\/BMBRep.2015.48.4.275"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Trainer PJ, Eastment C, Grossman AB, Wheeler MJ, Perry L, et al. (1993) The relationship between cortisol production rate and serial serum cortisol estimation in patients on medical therapy for Cushing\u2019s syndrome. Clin Endocrinol (Oxf) 39: 441\u2013443.","DOI":"10.1111\/j.1365-2265.1993.tb02391.x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Haissaguerre M, Puerto M, Nunes ML, Tabarin A (2020) Efficacy and tolerance of osilodrostat in patients with severe Cushing\u2019s syndrome due to non-pituitary cancers. Eur J Endocrinol 183: L7\u2013L9.","DOI":"10.1530\/EJE-20-0557"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Castinetti F, Nieman LK, Reincke M, Newell-Price J (2021) Approach to the patient treated with steroidogenesis inhibitors. J Clin Endocrinol Metab 106: 2114\u20132123.","DOI":"10.1210\/clinem\/dgab122"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Petersenn S (2021) Biochemical diagnosis of Cushing\u2019s disease: screening and confirmatory testing. Best Pract Res Clin Endocrinol Metab 35: 101519.","DOI":"10.1016\/j.beem.2021.101519"},{"key":"28","unstructured":"28 Capponi V, Carrasco C, Macchiavello S, Undurraga J, Campino C, et al. (2018) Depressive symptoms are associated with higher morning plasma cortisol in primary care subjects. Neuro Endocrinol Lett 39: 288\u2013293."},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Bonnet-Serrano F, Poirier J, Vaczlavik A, Laguillier-Morizot C, Blanchet B, et al. (2022) Differences in the spectrum of steroidogenic enzyme inhibition between Osilodrostat and Metyrapone in ACTH-dependent Cushing syndrome patients. Eur J Endocrinol 187: 315\u2013322.","DOI":"10.1530\/EJE-22-0208"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/72\/10\/72_EJ24-0696\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T03:55:41Z","timestamp":1759550141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/72\/10\/72_EJ24-0696\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej24-0696","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"EJ24-0696"}}